The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.